Adma Biologics (ADMA) Total Current Liabilities (2011 - 2026)

Adma Biologics (ADMA) has 14 years of Total Current Liabilities data on file, last reported at $69.5 million in Q4 2025.

• Quarterly Total Current Liabilities rose 25.2% year-over-year to $69.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $69.5 million (up 25.2% YoY) and the FY2025 annual result came in at $69.5 million, up 25.2% from the prior year.
• Total Current Liabilities rose to $69.5 million in Q4 2025, from $56.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $74.9 million in Q2 2025 to a low of $18.2 million in Q2 2021.
• A 5-year average of $43.4 million and a median of $43.1 million in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2021 — Total Current Liabilities jumped 96.3% — and 2023, when it decreased 5.85%.
• Tracing ADMA's Total Current Liabilities over 5 years: stood at $30.4 million in 2021, then increased by 29.26% to $39.3 million in 2022, then advanced by 26.84% to $49.8 million in 2023, then gained by 11.52% to $55.5 million in 2024, then climbed by 25.2% to $69.5 million in 2025.
• The last three Total Current Liabilities figures came in at $69.5 million (Q4 2025), $56.5 million (Q3 2025), and $74.9 million (Q2 2025), per Business Quant data.